Potential molecular approaches for the early diagnosis of lung cancer (Review)
- Authors:
- Chul Ho Oak
- Donald Wilson
- Hu Jang Lee
- Ho-Ju Lim
- Eun-Kee Park
-
Affiliations: Department of Internal Medicine, College of Medicine, Kosin University, Busan, Republic of Korea, Department of Occupational Toxicology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, Research Institute of Life Sciences, College of Veterinary Medicine, Gyeongsang National University, Chinju, Republic of Korea, Indoor Environment and Noise Research Division, National Institute of Environmental Research, Incheon, Republic of Korea, Department of Medical Humanities and Social Medicine, College of Medicine, Kosin University, Busan, Republic of Korea - Published online on: August 21, 2012 https://doi.org/10.3892/mmr.2012.1042
- Pages: 931-936
This article is mentioned in:
Abstract
 |
|
Lee YS, Oh YM, Shim TS, Kim WS, An JS, Choi CM and Jang SH: The clinical outcomes of photodynamic therapy in early lung cancer patients. Tuberc Respir Dis. 71:266–270. 2011. View Article : Google Scholar | |
|
Alberg AJ, Ford JG and Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132:29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ministry for Health, Welfare and Family Affairs. 2008 Annual Report of Cancer Statistics in Korea. Ministry for Health, Welfare and Family Affairs; Seoul: 2010 | |
|
Molina R, Filella X, Auge JM, et al: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC, and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis, and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 24:209–218. 2003. View Article : Google Scholar | |
|
American Cancer Society. Cancer Prevention & Early Detection Facts & Figures, 2011. American Cancer Society; Atlanta: 2011 | |
|
Scott WJ, Howington J, Feigenberg S, Movsas B and Pisters K; American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132:234S–242S. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch FR, Merrick DT and Franklin WA: Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J. 19:1151–1158. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY and Moro-Sibilot D: Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl. 39:36S–44S. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Brower V: Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst. 101:11–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A and Haick H: Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 4:669–673. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
van Klaveren RJ, Oudkerk M, Prokop M, et al: Management of lung nodules detected by volume CT scanning. N Engl J Med. 361:2221–2229. 2009. | |
|
Yau G, Lock M and Rodrigues G: Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer. 58:161–170. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J, Pouysségur J and Hofman P: High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 102:1627–1635. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF and Lam S: Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 27:2787–2792. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE II: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 25:5578–5583. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:5954–5958. 2000.PubMed/NCBI | |
|
Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA and Picchi MA: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 11:6505–6511. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gray RD, Duncan A, Noble D, Imrie M, O’Reilly DS, Innes JA, Porteous DJ, Greening AP and Boyd AC: Sputum trace metals are biomarkers of inflammatory and suppurative lung disease. Chest. 137:635–641. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kennedy TC, Miller Y and Prindiville S: Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. Chest. 117:72S–79S. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch J, Hansen KC, Burlingame AL and Matthay MA: Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol. 287:L1–L23. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sung HJ and Cho JY: Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 41:615–625. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 355:570–580. 2006. View Article : Google Scholar | |
|
Pleasance ED, Stephens PJ, O’Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 463:184–190. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
McDermott U, Downing JR and Stratton MR: Genomics and the continuum of cancer care. N Engl J Med. 364:340–350. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Verma M and Manne U: Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol. 60:9–18. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Habis AH, Vernon SD, Lee DR, Verma M and Unger U: Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev. 13:492–496. 2004.PubMed/NCBI | |
|
Martin KJ, Fournier MV, Reddy GP and Pardee AB: A need for basic research on fluid-based early detection biomarkers. Cancer Res. 70:5203–5206. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): S4–S11. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Parker CE, Pearson TW, Anderson NL and Borchers CH: Mass-spectrometry-based clinical proteomics–a review and prospective. Analyst. 135:1830–1838. 2010. | |
|
Qian B, Zhang H, Zhang L, Zhou X, Yu H and Chen K: Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer. 73:138–146. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chatterjee SK and Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1:37–50. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Verma M: Human epigenome and cancer. Human Genome Epidemiology. Khoury M, Bedrosian SR, Gwinn M, Higgins JPT, Ioannidis JPA and Little J: 2nd edition. Oxford University Press; London: pp. 551–558. 2009, View Article : Google Scholar | |
|
Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer. 2:210–219. 2002. View Article : Google Scholar | |
|
Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xue X, Zhu YM and Woll PJ: Circulating DNA and lung cancer. Ann NY Acad Sci. 1075:154–164. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 89:857–862. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 18:643–650. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Verma M and Srivastava S: Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3:755–763. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Verma M and Kumar D: Application of mitochondrial genome information in cancer epidemiology. Clin Chim Acta. 383:41–50. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Enokida H, Shiina H, Igawa M, et al: CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 64:5956–5962. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N and Dahiya R: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun. 316:1156–1162. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science. 270:484–487. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Showe MK, Vachani A, Kossenkov AV, et al: Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 69:9202–9210. 2009. View Article : Google Scholar | |
|
McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol. 28:429–440. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M and Schroth W: Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem. 56:1845–1853. 2010. View Article : Google Scholar | |
|
Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yanagihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 26:462–469. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Winder T, Ning Y, et al: A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 22:104–109. 2011. | |
|
Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kulpa J, Wojcik E, Radkowski A, Kolodziejski L and Stasik Z: CYFRA 21-1, TPA-M, TPS, SCC-Ag, and CEA in patients with squamous cell lung cancer, and in chemical industry workers as a reference group. Anticancer Res. 20:5035–5040. 2000.PubMed/NCBI | |
|
Lamy P, Grenier J, Kramar A and Pujol JL: Pro-gastrin-releasing peptide, neuron specific enolase, and chromogranin A as serum markers of small cell lung cancer. Lung Cancer. 29:197–203. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider J, Philipp M, Velcovsky HG, Morr H and Katz N: Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res. 23:885–893. 2003. | |
|
Cho WC, Yip TT, Cheng WW and Au JS: Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 102:1731–1735. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cremona M, Calabrò E, Randi G, De Bortoli M, Mondellini P, Verri C, Sozzi G, Pierotti MA, La Vecchia C, Pastorino U and Bongarzone I: Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer. 116:1326–1335. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Abdullah M, Marwitz S, Kähler D, Schultz H, Kugler C, Zabel P, Vollmer E and Goldmann T: Pulmonary haptoglobin: a new marker for adenocarcinomas of the lung? Pathology. 43:70–72. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R and Bharti A: Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics. 7:49–65. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Coward JI, Nathavitharana R and Popat S: True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. Lung Cancer. 75:133–135. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Song JS, Kim SY, Jo HJ, et al: The role and significance of biomarker for plasma G-CSF in patients with primary lung cancer. Tuber Respir Dis. 66:444–450. 2009. View Article : Google Scholar | |
|
Hanash SM, Pitteri SJ and Faca VM: Mining the plasma proteome for cancer biomarkers. Nature. 452:571–579. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Taguchi A, Politi K, Pitteri SJ, et al: Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20:289–299. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ, Yang JH and Chung KH: Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1. J Proteome Res. 10:269–276. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Yang S, Lin X, Bu L, Nan Y, Huo S and Shang W: Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer. Diagn Pathol. 5:602010. View Article : Google Scholar : PubMed/NCBI | |
|
Rahman SM, Gonzalez AL, Li M, et al: Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res. 71:3009–3017. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Seydel C: Quantum dots get wet. Science. 300:80–81. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Guha U, Chaerkady R, Marimuthu A, et al: Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA. 105:14112–14117. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J and Bennett KL: Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 10:182–190. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM and Bigbee WL: Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res. 9:6440–6449. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato K: Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 17:7808–7815. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kaiser J: Medicine. Cancer’s circulation problem. Science. 327:1072–1074. 2010. | |
|
Pantel K, Alix-Panabieres C and Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol. 6:339–351. 2009. View Article : Google Scholar : PubMed/NCBI |
